🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with data suggesting in excess of 82 million new cases each year. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in recent days for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, also received approval in close succession. This drug, which is also used to treat UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Results and Worldwide Availability

Based on findings released by a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which uses an injection and a pill. The study enrolled nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the ability to license and sell the drug in many low-income and middle-income countries.

Doctors treating patients have expressed positive views. The availability of a one-pill regimen like this is seen as a "revolutionary step" for managing the epidemic. This is deemed essential to alleviate the strain of the infection for patients and to halt the transmission of extremely resistant gonorrhoea globally.